Phaseline

Companies › Bionic Sight

Bionic Sight: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Ophthalmology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BS01–Phase 1Retinitis Pigmentosa; Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04278131BS01Phase 1Retinitis PigmentosaOphthalmologyDec 2026
NCT07158775BS01Phase 1Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)OphthalmologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.